The India Pharmaceutical Market Strategic Intelligence Suite 2026-2031 combines two full-length strategic research reports -- the India Pharmaceuticals Industry Report (consumption/demand-side, USD 27.8 billion in 2025, 8.4% CAGR to USD 50.0 billion by 2031) and the India Pharmaceuticals Manufacturing Market Report (production/supply-side, USD 30.5 billion in 2025, 10.5% CAGR to USD 55.5 billion by 2031) -- plus a cross-report executive presentation, summary document, and interactive infographic.
Most coverage of India's pharmaceutical industry answers one of two distinct questions without making clear which: the value India manufactures, or the value Indians actually buy. This Suite closes that gap with cross-report analysis including India's real export orientation (Divi's Laboratories exports 95%+ of output, Gland Pharma roughly 80%), the real Hyderabad manufacturing concentration finding (35% of India's total exports from one city), and the genuinely uneven PLI scheme disbursement pattern.
A reader evaluating India pharmaceutical exposure -- whether for manufacturing capacity investment, domestic market entry, or portfolio analysis -- gets both perspectives in one integrated purchase.
Most coverage of India's pharmaceutical industry answers one of two distinct questions without making clear which: the value India manufactures, or the value Indians actually buy. This Suite closes that gap with cross-report analysis including India's real export orientation (Divi's Laboratories exports 95%+ of output, Gland Pharma roughly 80%), the real Hyderabad manufacturing concentration finding (35% of India's total exports from one city), and the genuinely uneven PLI scheme disbursement pattern.
A reader evaluating India pharmaceutical exposure -- whether for manufacturing capacity investment, domestic market entry, or portfolio analysis -- gets both perspectives in one integrated purchase.
Scope of India Pharmaceutical Market Strategic Intelligence Suite 2026-2031
- This Suite includes the complete India Pharmaceuticals Industry Strategic Research Report.
- This Suite includes the complete India Pharmaceuticals Manufacturing Market Strategic Research Report.
- This Suite includes a 12-slide executive presentation comparing both reports' key findings.
- This Suite includes a cross-report summary document explaining the demand-supply linkage, including the Hyderabad concentration analysis.
- This Suite includes an interactive infographic for board-level and investor-facing use.
- This Suite covers 21 unique companies across both underlying reports.
Who can use the India Pharmaceutical Market Strategic Intelligence Suite?
This Suite is ideal for people who need both sides of India's pharmaceutical value chain in one integrated resource. Some of the intended users are:- Investors evaluating full India value-chain exposure across manufacturing and commercial positioning
- Supply chain executives assessing India manufacturing concentration risk
- C-level executives requiring comprehensive India strategic intelligence for board presentations
- Anyone operating across India's pharmaceutical demand and supply value chain.
Table of Contents
1. Suite Overview2. Report 1: India Pharmaceuticals Industry (full 13-chapter report)
3. Report 2: India Pharmaceuticals Manufacturing (full 13-chapter report)
4. Suite Bonus Deliverables (Executive Presentation, Summary Document, Infographic)
Companies Mentioned
- Sun Pharmaceutical
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- Cipla
- Lupin
- Zydus Lifesciences
- Biocon
- Alkem Laboratories
- Torrent Pharma
- Divi's Laboratories
- Piramal Pharma
- Mankind Pharma
- Gland Pharma
- Ipca Laboratories
- Granules India
- Jubilant Pharmova
- Ajanta Pharma
- Natco Pharma
- Abbott India
- Pfizer India
- Sanofi India
